Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

Inclusion Criteria: 1. Age ≥18; 2. Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) 3. Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3; 4. No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency 5. Cooperative Oncology Group-Status (ECOG Status) score 0-2; 6. Expected survival ≥3 months; 7. Feasible abdomen and pelvic cavity MRI/CT; 8. Good compliance, signed informed consent voluntarily. Exclusion Criteria: 1. Previous radiotherapy at the target lesion site; 2. History of active inflammatory bowel disease or severe stomach and duodenal ulcers; 3. Human immunodeficiency virus (HIV) infected persons; 4. active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit); 5. suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication: 6. patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin); 7. neurological or mental disorders that affect cognitive ability; 8. Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy; 9. those who cannot follow up regularly as prescribed by the doctor; 10. Other reasons not suitable for participating in this study as judged by the researcher.